A Proprietary Synergistic Growth Model Spanning Branded Drugs, Generics and CMO Services
First written in FY2016-Q3. 10 of 11 entries say "Restated". Latest entry: FY2019-Q3.
No other company in this theme has enough history to compare yet.
- FY2019-Q3RestatedAnnual report
「We are developing a unique synergistic growth model combining branded drugs, generics and CMO services in our strategic areas.」
The company continues to promote its unique synergistic growth model combining branded drugs, generics and CMO services. - FY2019-Q2RestatedAnnual report
「We are developing a unique synergistic growth model combining branded drugs, generics and CMO services in our strategic areas.」
The company continues to promote its unique synergistic growth model combining branded drugs, generics and CMO services. - FY2019-Q1RestatedAnnual report
「The company is working to build a distinctive synergistic growth model combining branded drugs, generics, and CMO in its strategic areas.」
The company continues to promote its unique business model combining branded drugs, generics and CMO services. - FY2018-Q3RestatedAnnual report
「The company is working to build a distinctive synergistic growth model combining branded drugs, generics, and CMO in its strategic areas.」
The company continues to promote its unique business model combining branded drugs, generics and CMO services. - FY2018-Q2RestatedAnnual report
「The company is working to build a distinctive synergistic growth model combining branded drugs, generics, and CMO in its strategic areas.」
The company continues to promote its unique business model combining branded drugs, generics and CMO services. - FY2018-Q1RestatedAnnual report
「The company is working to build a distinctive synergistic growth model combining branded drugs, generics, and CMO in its strategic areas.」
The company continues to promote a business model combining branded drugs, generics and CMO services. - FY2017RestatedAnnual report
「We will renew our corporate functions, rebuild our business operating structure and create a unique synergistic growth model centered on branded drugs and generics.」
The company continues to promote its unique model combining branded drugs and generics, and also refers to rebuilding its business operating structure. - FY2017-Q3RestatedAnnual report
「The company is working to build a distinctive synergistic growth model combining branded drugs, generics, and CMO in its strategic areas.」
The company continues to promote its unique model combining branded drugs, generics and CMO services. - FY2017-Q2RestatedAnnual report
「The company is working to build a distinctive synergistic growth model combining branded drugs, generics, and CMO in its strategic areas.」
The company continues to promote its unique model combining branded drugs, generics and CMO services. - FY2017-Q1RestatedAnnual report
「The company is working to build a distinctive synergistic growth model combining branded drugs, generics, and CMO in its strategic areas.」
The company continues to promote its unique model combining branded drugs, generics and CMO services. - FY2016-Q3First statedAnnual report
「The company is working to build a distinctive synergistic growth model combining branded drugs, generics, and CMO in its strategic areas.」
The company explicitly disclosed for the first time a business model combining branded drugs, generics, and CMO.